Peptide and protein drugs: The study of their metabolism and catabolism by mass spectrometry

Mass Spectrometry Reviews

Volumn 31, Issue 1, 2012, Pages 110-133

  Katsila, Theodora ^a   Siskos, Alexandros P ^a   Tamvakopoulos, Constantin ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

biopharmaceuticals; catabolism; degradation; LC MS MS; mass spectrometry; metabolism; metabolite; peptide protein drug; quantification; stability; structure elucidation

Indexed keywords

BIOPHARMACEUTICALS; CATABOLISM; LC-MS/MS; QUANTIFICATION; STRUCTURE ELUCIDATION;

BIODEGRADATION; CONVERGENCE OF NUMERICAL METHODS; DEGRADATION; MASS SPECTROMETRY; METABOLITES; PEPTIDES; PHYSIOLOGY;

METABOLISM;

DRUG; PEPTIDE; PROTEIN;

CHEMISTRY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; REVIEW; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, LIQUID; HUMANS; MASS SPECTROMETRY; PEPTIDES; PHARMACEUTICAL PREPARATIONS; PROTEINS; TANDEM MASS SPECTROMETRY;

EID: 84155165533     PISSN: 02777037     EISSN: 10982787     Source Type: Journal    
DOI: 10.1002/mas.20340     Document Type: Review

References (154)

1. Aebersold R, Mann M,. 2003. Mass spectrometry-based proteomics. Nature 422: 198-207. (Pubitemid 36362757)
2. Andrews DJ, Cramb R,. 2002. Cyclosporin: Revisions in monitoring guidelines and review of current analytical methods. Ann Clin Biochem 39: (Pt 5): 424-435. (Pubitemid 34983437)
3. Ashitani J, Matsumoto N, Nakazato M,. 2009. Ghrelin and its therapeutic potential for cachectic patients. Peptides 30 (10): 1951-1956.
4. Aydin S, Karatas F, Geckil H,. 2008. Simultaneous quantification of acylated and desacylated ghrelin in biological fluids. Biomed Chromatogr 22 (12): 1354-1359.
5. Babu CV, Lho DS, Yoo YS,. 2006. Monitoring the neuropeptide metabolites by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Pharm Biomed Anal 40 (1): 136-141. (Pubitemid 43061228)
6. Bakhtiar R, Guan Z,. 2006. Electron capture dissociation mass spectrometry in characterization of peptides and proteins. Biotechnol Lett 28 (14): 1047-1059.
7. Balani SK, Xu X, Arison BH, Silva MV, Gries A, DeLuna FA, Cui D, Kari PH, Ly T, Hop CE, Singh R, Wallace MA, Dean DC, Lin JH, Pearson PG, Baillie TA,. 2000. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab Dispos 28 (11): 1274-1278.
8. Ban K, Kim KH, Cho CK, Sauvé M, Diamandis EP, Backx PH, Drucker DJ, Husain M,. 2010. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 151 (4): 1520-1531.
9. Banga AK, Chien YW,. 1988. Systemic delivery of therapeutic peptides and proteins. Int J Pharm 48: 15-50.
10. Bernkop-Schnurch A, Schmitz T,. 2007. Presystematic metabolism of orally administered peptide drugs and strategies to overcome it. Curr Drug Metab 8 (5): 509-517. (Pubitemid 47603415)
11. Braszko JJ,. 2004. Involvement of D1 dopamine receptors in the cognitive effects of angiotensin IV and des-Phe6 angiotensin IV. Peptides 25: 1195-1203. (Pubitemid 38885734)
12. Brossard JH, Yamamoto LN, D'Amour P,. 2002. Parathyroid hormone metabolites in renal failure: Bioactivity and clinical implications. Semin Dial 15: 196-201. (Pubitemid 41765931)
13. Brown JA, Cobb CS, Frankling SC, Rankin JC,. 2005. Activation of the newly discovered cyclostome rennin-angiotensin system in the river lamprey Lampetra fluviatilis. J Exp Biol 208: 223-232. (Pubitemid 40307226)
14. Bujak-Gizycka B, Madej J, Wolkow PP, Olszanecki R, Drabik L, Rutowski J, Korbut R,. 2007. Measurement of angiotensin metabolites in organ bath and cell culture experiments by liquid chromatography-electrospray ionisation-mass spectrometry (LC-ESI-MS). J Physiol Pharmacol 58: 529-540. (Pubitemid 47523095)
15. Caliceti P, Veronese FM,. 2003. Pharmacokinetic and biodistribution properties of poly (ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 55: 1261-1277. (Pubitemid 37464561)
16. Camilleri M, Papathanasopoulos A, Odunsi ST,. 2009. Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 6 (6): 343-352. Review.
17. Carone FA, Peterson DR,. 1980. Hydrolysis and transport of small peptides by the proximal tubule. Am J Physiol Renal Physiol 238: F151-F158. (Pubitemid 10118194)
18. Chang D, Kolis SJ, Linderholm KH, Julian TF, Nachi R, Dzerk AM, Lin PP, Lee JW, Bansal SK,. 2005. Bioanalytical method development and validation for a large peptide HIV fusion inhibitor (Enfuvirtide, T-20) and its metabolite in human plasma using LC-MS/MS. J Pharm Biomed Anal 38: 487-496. (Pubitemid 40733186)
19. Christians U, Sewing KF,. 1993. Cyclosporin metabolism in transplant patients. Pharmacol Ther 57: 291-345. (Pubitemid 23175384)
20. Christin-Maitre S, Vasseur C, Fauser B, Bouchard P,. 2000. Bioassays of gonadotropins. Methods 21: 51-57. (Pubitemid 32896770)
21. Cong WN, Golden E, Pantaleo N, White CM, Maudsley S, Martin B,. 2010. Ghrelin receptor signaling: A promising therapeutic target for metabolic syndrome and cognitive dysfunction. CNS Neurol Disord Drug Targets 9 (5): 557-563.
22. Coon JJ, Ueberheide B, Syka JEP, Dryhurst DD, Ausio J, Shabanowitz J, Hunt DF,. 2005. Protein identification using sequential ion/ion reactions and tandem mass spectrometry. Proc Natl Acad Sci USA 102: 9463-9468. (Pubitemid 40981704)
23. Copeland KR, Thliveris JA, Yatscoff RW,. 1990. Toxicity of cyclosporine metabolites. Ther Drug Monit 12: 525-532.
24. Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG,. 2006. Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 7: 367-374.
25. Dai Y, Iwanaga K, Lin YS, Hebert MF, Davis CL, Huang W, Kharasch ED, Thummel KE,. 2004. In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol 68 (9): 1889-1902. (Pubitemid 39278511)
26. De Smet B, Mitselos A, Depoortere I,. 2009. Motilin and ghrelin as prokinetic drug targets. Pharmacol Ther 123 (2): 207-223. Review.
27. Deacon CF,. 2004. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53: 2181-2189. (Pubitemid 39145569)
28. DeVriese C, Gregoire F, Lema-Kisoka R, Waelbroeck M, Robberecht P, Delporte C,. 2004. Ghrelin degradation by serum and tissue homogenates: Identification of the cleavage sites. Endocrinology 145: 4997-5005. (Pubitemid 39551118)
29. Domon B, Aebersold R,. 2006. Mass spectrometry and protein analysis. Science 312: 212-217.
30. Duckworth WC, Bennet RG, Hamel FG,. 1997. The significance of intracellular insulin to insulin action. J Invest Med 45: 20-27. (Pubitemid 127453333)
31. Duckworth WC, Bennet RG, Hamel FG,. 1998. Insulin degradation: Progress and potential. Endocr Rev 19: 608-624. (Pubitemid 28467714)
32. Dunn CJ, Waqstaff AJ, Perry CM, Plosker GL, Goa KL,. 2001. Cyclosporin: An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Drugs 61: 1957-2016.
33. Edwards CMB, Cohen MA, Bloom SR,. 1999. Peptides as drugs. Q J Med 92: 1-4. (Pubitemid 29034093)
34. Elased KM, Cunha TS, Marcondes FK, Morris M,. 2008. Brain angiotensin-converting enzymes: Role of angiotensin-converting enzyme 2 in processing angiotensin II in mice. Exp Physiol 93 (5): 665-675. (Pubitemid 351595055)
35. Falciani C, Lozzi L, Pini A, Corti F, Fabbrini M, Bernini A, Lelli B, Niccolai N, Bracci L,. 2007. Molecular basis of branched peptides resistance to enzyme proteolysis. Chem Biol Drug Des 69 (3): 216-221. (Pubitemid 46608454)
36. Falck P, Guldseth H, Asberg A, Midtvedt K, Reubsaet JLE,. 2007. Determination of ciclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry. J Chromatogr B 852: 345-352. (Pubitemid 46830123)
37. Fang ZG, You BG, Chen YG, Zhang JK, Liu YQ, Zhang XN, Zhang Q,. 2010. Analysis of cyclosporine A and its metabolites in rat urine and feces by liquid chromatography-tandem mass spectrometry. J Chromatogr B 878 (15-16): 1153-1162.
38. Fasano A,. 1998. Novel approaches for oral delivery of macromolecules. J Pharm Sci 87: 1351-1356. (Pubitemid 28514140)
39. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM,. 1989. Electrospray ionization for mass spectrometry of large biomolecules. Science 246: 64-71. (Pubitemid 19252085)
40. Fonseca C, Dominques P, Reis A, Domingues MRM,. 2008. Identification of leucine-enkephalin radical oxidation products by liquid chromatography tandem mass spectrometry. Biomed Chromatogr 22: 947-959.
41. Furlanut M, Baraldo M, Galla F, Marzocchi V, Pea F,. 1996. Cyclosporin nephrotoxicity in relation to its metabolism in psoriasis. Pharmacol Res 33: 349-352. (Pubitemid 26413595)
42. Gedulin BR, Smith PA, Jodka CM, Chen K, Bhavsar S, Nielsen LL, Parkes DG, Young AA,. 2008. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int J Pharm 356 (1-2): 231-238.
43. Glish GL, Vachet RW,. 2003. The basics of mass spectrometry in the twenty-first century. Nat Rev Drug Discov 2 (2): 140-150. Review. (Pubitemid 37361646)
44. Goldstein A, Tachibana S, Lowney LI, Hunkapillar M, Hood L,. 1979. Dynorphin (1-13), an extraordinary potent opioid peptide. Proc Natl Acad Sci USA 76: 6666-6670. (Pubitemid 10166229)
45. Gonzalez FJ, Tukey RH,. 2006. Drug metabolism. In:, Brunton LL, Lazo JS, Parker KL, editors. Goodman & Gilman's: The pharmacological basis of therapeutics. New York: McGraw-Hill. pp. 71-91.
46. Han X, Aslanian A, Yates JR III., 2008. Mass spectrometry for proteomics. Curr Opin Chem Biol 12: 483-490.
47. Headlam HA, Davies MJ,. 2004. Markers of protein oxidation: Different oxidants give rise to variable yields of bonds and released carbonyl products. Free Radic Biolo Med 36: 1175-1184. (Pubitemid 38479871)
48. Hong SY, Oh JE, Kwon M, Choi MJ, Lee JH, Lee BL, Moon HM, Lee KH,. 1998. Identification and characterisation of novel antimicrobial decapeptides generated by combinational chemistry. Antimicrob Agents Chemother 42: 2534-2541. (Pubitemid 28462890)
49. Hop CECA,. 2004. Applications of quadrupole-time-of-flight mass spectrometry to facilitate metabolite identification. Am Pharm Rev 7: 76-79.
50. Horning EC, Caroll DI, Dzidic I, Haegele KD, Horning MG, Stillwell RN,. 1974. Atmospheric pressure ionization (API) mass spectrometry. Solvent-mediated ionization of samples introduced in solution and in a liquid chromatograph effluent stream. J Chromatogr Sci 12: 725-729.
51. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinanthsinghji DJ, Dean DC, Melillo DG, Patchett AA, Nargund R, Griffin PR, DeMartino JA, Gupta SK, Schaeffer JM, Smith RG, Van der Ploeg LH,. 1996. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273: 974-977. (Pubitemid 26275178)
52. Hruby VJ,. 2005. On the topic of peptide research and drug discovery. J Peptide Res 66: 309-310. (Pubitemid 41784376)
53. Huet T, Kerbarh O, Schols D, Clayette P, Gauchet C, Dubreucq G, Vincent L, Bompais H, Mazinghien R, Querolle O, Salvador A, Lemoine J, Lucidi B, Balzarini J, Petitou M,. 2010. Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 54 (1): 134-142.
54. IMS Health-Global report, 2009.
55. John H, Walden M, Schafer S, Genz S, Forssmann WG,. 2004. Analytical procedures for quantification of peptides in pharmaceutical research by liquid chromatography-mass spectrometry. Anal Bioanal Chem 378 (4): 883-897. (Pubitemid 40890201)
56. John H, Maronde E, Forssmann WG, Meyer M, Adermann K,. 2008. N-Terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity. Eur J Med Res 13 (2): 73-78. (Pubitemid 351385091)
57. Katsila T, Balafas E, Liapakis G, Limonta P, Montagnani Marelli M, Gkountelias K, Tselios T, Kostomitsopoulos N, Matsoukas J, Tamvakopoulos C,. 2011. Evaluation of a stable gonadotropin releasing hormone analogue in mice for the treatment of endocrine disorders and prostate cancer. J Pharmacol Exp Ther 336 (3): 613-623.
58. Kempkes-Koch M, Fobker M, Erren M, August C, Gerhardt U, Suwelack B, Hohage H,. 2001. Cyclosporine A metabolite AM19 as a potential biomarker in urine for CSA nephropathy. Transplant Proc 33: 2167-2169. (Pubitemid 33762671)
59. Kemsley J,. 2009. Analyzing protein drugs. Chem Eng News, July 20, p20-23.
60. Klintenberg R, Andrén PE,. 2005. Altered extracellular striatal in vivo biotransformation of the opioid neuropeptide dynorphin A(1-17) in the unilateral 6-OHDA rat model of Parkinson's disease. J Mass Spectrom 40 (2): 261-270. (Pubitemid 40327265)
61. Kreuzer H, Massey A,. 2000. Recombinant DNA and biotechnology. Washington, DC: ASM Press.
62. Krondahl E, Von Euler-Chelpin H, Orzechowski A, Ekström G, Lennernäs H,. 2000. Investigations of the in-vitro metabolism of three opioid tetrapeptides by pancreatic and intestinal enzymes. J Pharm Pharmacol 52 (7): 785-795. (Pubitemid 30461912)
63. Kuuranne T, Thomas A, Leinonen A, Delahaut P, Bosseloir A, Schänzer W, Thevis M,. 2008. Insulins in equine urine: Qualitative analysis by immunoaffinity purification and liquid chromatography/tandem mass spectrometry for doping control purposes in horse-racing. Rapid Commun Mass Spectrom 22 (3): 355-362. (Pubitemid 351212861)
64. Lan LB, Dalton JT, Schuetz EG,. 2000. Mdr1 limits CYP3A metabolism in vivo. Mol Pharmacol 58: 863-869.
65. Lanckmans K, Sarre S, Smolders I, Michotte Y,. 2007. Use of a structural analogue versus a stable isotope labeled internal standard for the quantification of angiotensin IV in rat brain dialysates using nano-liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 21 (7): 1187-1195. (Pubitemid 46506572)
66. Lanckmans K, Stragier B, Sarre S, Smolders I, Michotte Y,. 2007. Nano-LC-MS/MS for the monitoring of angiotensin IV in rat brain microdialysates: Limitations and possibilities. J Sep Sci 30: 2217-2224. (Pubitemid 47497022)
67. Langub MC, Monier-Faugere M-C, Wang G, Williams JP, Koszewski NJ, Malluche HH,. 2003. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 144: 1135-1138. (Pubitemid 36428451)
68. Lee KC, Chae SY, Kim TH, Lee S, Lee ES, Youn YS,. 2009. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent. Regul Pept 152: 101-107.
69. Leung KP, Crowe TD, Abercrombie JJ, Molina CM, Bradshaw CJ, Jensen CL, Luo Q, Thompson GA,. 2005. Control of oral biofilm formation by an antimicrobial decapeptide. J Dent Res 84: 1172-1177. (Pubitemid 43827787)
70. Levy G,. 1994. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56: 248-252. (Pubitemid 24323915)
71. Liao S, Zhang ZQ, Ruan JX, Qi JK, Liu KL,. 2008. Degradation of salmon calcitonin in rat kidney and liver homogenates. Pharmazie 63 (10): 743-747.
72. Liao S, Qie JK, Xue M, Zhang ZQ, Liu KL, Ruan JX,. 2010. Metabolic stability of human parathyroid hormone peptide hPTH (1-34) in rat tissue homogenates: Kinetics and products of proteolytic degradation. Amino Acids 38 (5): 1595-1605.
73. Lin JH,. 2009. Pharmacokinetics of biotech drugs: Peptides, proteins and monoclonal antibodies. Curr Drug Metab 10 (7): 661-691.
74. Lobo ED, Hansen RJ, Balthasar JP,. 2004. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93: 2645-2668. (Pubitemid 39506617)
75. Loffet A,. 2002. Peptides as drugs: Is there a market? J Peptide Sci 8: 1-7. (Pubitemid 34121308)
76. Lohr JW, Willsky GR, Acara MA,. 1998. Renal drug metabolism. Pharmacol Rev 50: 107-141. (Pubitemid 28158844)
77. Lu Y, Yang J, Sega E,. 2006. Issues related to targeted delivery of proteins and peptides. AAPS J 8: E466-E478. (Pubitemid 44149415)
78. Ma S, Subramanian R,. 2006. Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry. J Mass Spectrom 41: 1121-1139. (Pubitemid 44454166)
79. Mager DE,. 2006. Target-mediated drug disposition and dynamics. Biochem Pharmacol 72: 1-10. (Pubitemid 43795346)
80. Mager DE, Jusko WJ,. 2001. General Pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharm Pharmacol 28: 507-532. (Pubitemid 34289541)
81. Magnusson K, Hallberg M, Bergquist J, Nyberg F,. 2007. Enzymatic conversion of dynorphin A in the rat brain is affected by administration of nandrolone decanoate. Peptides 28 (4): 851-858. (Pubitemid 46349328)
82. Mahato RI, Narang AS, Thoma L, Miller DD,. 2003. Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 20: 153-214. (Pubitemid 37237279)
83. Malluche HH, Mawad H, Trueba D, Monier-Faugere MC,. 2003. Parathyroid hormone assays-evolution and revolutions in the care of dialysis patients. Clin Nephrol 59: 313-318. (Pubitemid 36592205)
84. Matsui T, Tamaya K, Kawasaki T, Osajima Y,. 1999. Determination of angiotensin metabolites in human plasma by fluorometric high-performance liquid chromatography using a heart-cut column-switching technique. J Chromatogr B 729: 89-95. (Pubitemid 29264112)
85. McGregor DP,. 2008. Discovering and improving novel peptide therapeutics. Curr Opin Chem Biol 8: 616-619.
86. McMartin C,. 1992. Pharmacokinetics of peptides and proteins: Opportunities and challenges. Adv Drug Res 22: 39-106.
87. Meibohm B,. 2006. The role of pharmacokinetics and pharmacodynamics in the development of biotech drugs. In:, Meibohm B, editor. Pharmacokinetics and pharmacodynamics of biotech drugs: Principles and case studies. Weinheim: Wiley-VCH Verlag GmbH & Co. pp. 3-13.
88. Merrifield RB,. 1963. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc 85: 2149-2154.
89. Mire-Sluis AR,. 2001. Progress in the use of biological assays during the development of biotechnology products. Pharm Res 18: 1239-1246. (Pubitemid 32846315)
90. Muller S, Hochhaus G,. 1995. Metabolism of dynorphin A 1-13 in human blood and plasma. Pharm Res 12: 1165-1170.
91. Müller S, Grundy BL, Hochhaus G,. 1996. Metabolism of dynorphin A 1-13 in human CSF. Neurochem Res 21 (10): 1213-1219. (Pubitemid 26357273)
92. Murphy RE, Kinhikar AG, Shields MJ, Del Rosario J, Preston R, Levin N, Ward GH,. 2010. Combined use of immunoassay and two-dimensional liquid chromatography mass spectrometry for the detection and identification of metabolites from biotherapeutic pharmacokinetic samples. J Pharm Biomed Anal 53 (3): 221-227.
93. Murray TM, Rao LG, Divieti P, Bringhurst FR,. 2005. Parathyroid hormone secretion and action: Evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl-terminal lignads. Endocr Rev 26: 78-113. (Pubitemid 40209388)
94. Na DH, Youn YS, Lee SD, Son MW, Kim WB, DeLuca PP, Lee KC,. 2003. Monitoring of peptide acylation inside degrading PLGA microspheres by capillary electrophoresis and MALDI-TOF mass spectrometry. J Control Release 92: 291-299. (Pubitemid 38366152)
95. Na DH, Youn YS, Park EJ, Lee JM, Cho OR, Lee KR, Lee SD, Yoo SD, Lee KC,. 2004. Stability of PEGylated salmon calcitonin in nasal mucosa. J Pharm Sci 93: 256-261. (Pubitemid 38174248)
96. Na DH, Faraj J, Capan Y, Leung KP, DeLuca PP,. 2007. Stability of antimicrobial decapeptide (KSL) and its analogues for delivery in the oral cavity. Pharm Res 24: 1544-1550. (Pubitemid 46988221)
97. Naik GO, Moe GW,. 2000. Simultaneous separation of angiotensin and endothelin peptide families by high-performance liquid chromatography: Application to the specific radioimmunoassay measurement of angiotensin II or endothelin-1 from tissue. J Chromatogr A 870 (1-2): 349-361. (Pubitemid 30077437)
98. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH,. 2001. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434-1441. (Pubitemid 32402100)
99. Nielsen LL,. 2005. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today 10: 703-710. (Pubitemid 40724552)
100. Nikolopoulos D, Theocharis S, Kouraklis G,. 2010. Ghrelin: A potential therapeutic target for cancer. Regul Pept 163 (1-3): 7-17.
101. Nydahl KS, Pierson J, Nyberg F, Caprioli RM, Andrén PE,. 2003. In vivo processing of LVV-hemorphin-7 in rat brain and blood utilizing microdialysis combined with electrospray mass spectrometry. Rapid Commun Mass Spectrom 17 (8): 838-844. (Pubitemid 36433169)
102. Okada H, Toguchi H,. 1995. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carr Syst 12: 1-99.
103. Olyaei AJ, de Mattos AM, Bennett WM,. 2001. Nephrotoxicity of immunosuppressive drugs: New insight and preventive strategies. Curr Opin Crit Care 7: 384-389. (Pubitemid 34020400)
104. Petricoin EF III, Liotta LA,. 2003. Mass spectrometry-based diagnostics: The upcoming devolution in disease detection. Clin Chem 49: 533-534. (Pubitemid 36379514)
105. Petricoin EF III, Ornstein DK, Paweletz CP, Ardekani A, Hackett PA, Hitt BA,. 2002. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 94: 1576-1578. (Pubitemid 35277282)
106. Pharmaceutical Research Manufacturers of America. 2008. Medicines in development-biotechnology-survey. Washington, DC: Pharmaceutical Research Manufacturers of America.
107. Prakash C, Shaffer CL, Nedderman A,. 2007. Analytical strategies for identifying drug metabolites. Mass Spectrom Rev 26: 340-369. (Pubitemid 46750374)
108. Pritchard DI,. 2005. Sourcing a chemical succession for cyclosporin from parasites and human pathogens. Drug Discov Today 10: 688-691. (Pubitemid 40724550)
109. Prokai L, Kim HS, Zharikova A, Roboz J, Ma L, Deng L, Simonsick WJ, Jr., 1998. Electrospray ionization mass spectrometric and liquid chromatographic-mass spectrometric studies on the metabolism of synthetic dynorphin A peptides in brain tissue in vitro and in vivo. J Chromatogr A 800 (1): 59-68. (Pubitemid 28154864)
110. Ragnarsson U,. 2007. The Nobel trail of Vincent du Vigneaud. J Pept Sci 13: 431-433. (Pubitemid 47082892)
111. Ramírez-Molina C, Heudi O, Pullen M, Marshall PS,. 2006. Study of bradykinin metabolism by rat lung tissue membranes and rat kidney brush border membranes by HPLC with inductively coupled plasma-mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry. J Pept Sci 12 (3): 220-226. (Pubitemid 43349363)
112. Rauh M, Groschl M, Rascher W,. 2007. Simultaneous quantification of ghrelin and desacyl-ghrelin by liquid chromatography tandem mass spectrometry in plasma, serum and cell supernatants. Clin Chem 53: 902-910. (Pubitemid 46744247)
113. Reed B, Zhang Y, Chait BT, Kreek MJ,. 2003. Dynorphin A(1-17) biotransformation in striatum of freely moving rats using microdialysis and matrix-assisted laser desorption/ionization mass spectrometry. J Neurochem 86 (4): 815-823. (Pubitemid 36988794)
114. Rose MP, Gaines Das RE, Balen AH,. 2000. Definition and measurement of follicle stimulating hormone. Endocr Rev 21 (1): 5-22. Review. (Pubitemid 32260393)
115. Rostami-Hodjegan A, Tucker GT,. 2007. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6: 140-148. (Pubitemid 46745341)
116. Sato AK, Viswanathan M, Kent RB, Wood R,. 2006. Therapeutic peptides: Technological advances driving peptides into development. Curr Opin Biotechnol 17: 638-642. (Pubitemid 44791908)
117. Satou M, Nishi Y, Yoh J, Hattori Y, Sugimoto H,. 2010. Identification and characterization of acyl-protein thioesterase 1/lysophospholipase I as a ghrelin deacylation/lysophospholipid hydrolyzing enzyme in fetal bovine serum and conditioned medium. Endocrinology 151 (10): 4765-4775.
118. Savoy LA, Jones RML, Pochon S, Davies JG, Muir AV, Offord RE, Rose K,. 1988. Identification by fast atom bombardment mass spectrometry of insulin fragments produced by insulin proteinase. Biochem J 249: 215-222.
119. Schey KL, Finley EL,. 2000. Identification of peptide oxidation by tandem mass spectrometry. Acc Chem Res 33: 299-306.
120. Schwyzer R,. 1996. First steps in peptide science. Protein Sci 5: 2358-2363.
121. Siskos AP, Katsila T, Balafas E, Kostomitsopoulos N, Tamvakopoulos C,. 2009. Simultaneous absolute quantification of the glucose-dependent insulinotropic polypeptides GIP1-42 and GIP3-42 in mouse plasma by LC/ESI-MS/MS: Preclinical evaluation of DP-IV inhibitors. J Proteome Res 8: 3487-3496.
122. Sofianos ZD, Katsila T, Kostomitsopoulos N, Balafas V, Matsoukas J, Tselios T, Tamvakopoulos C,. 2008. In vivo evaluation and in vitro metabolism of leuprolide in mice-Mass spectrometry based biomarker measurement for efficacy and toxicity. J Mass Spectrom 43: 1381-1392.
123. Tamvakopoulos C,. 2007. Mass spectrometry for the quantification of bioactive peptides in biological fluids. Mass Spectrom Rev 26: 389-402. (Pubitemid 46750376)
124. Tanaka K,. 2003. The origin of macromolecule ionization by laser irradiation (Nobel lecture). Angew Chem Int Ed Engl 42: 3860-3870.
125. Tang L, Persky AM, Hochhaus G, Meibohm B,. 2004. Pharmacokinetic aspects of biotechnology products. J Pharm Sci 93: 2184-2198.
126. Thevis M, Schanzer W,. 2007. Mass spectrometric identification of peptide hormones in doping control analysis. Analyst 132: 287-291. (Pubitemid 46494497)
127. Thevis M, Thomas A, Schanzer W,. 2008. Mass spectrometric determination of insulins and their degradation products in sports drug testing. Mass Spectrom Rev 27: 35-50. (Pubitemid 350279865)
128. Thevis M, Thomas A, Schänzer W,. 2010. Insulin. Handb Exp Pharmacol 195: 209-226. Review.
129. Thomas A, Thevis M, Delahaut P, Bosseloir A, Schänzer W,. 2007. Mass spectrometric identification of degradation products of insulin and its long-acting analogues in human urine for doping control purposes. Anal Chem 79 (6): 2518-2524. (Pubitemid 46449034)
130. Thorpe R, Wadhwa M, Page C, Mire-Sluis A,. 1999. Bioassays for the characterization and control of therapeutic cytokines: Determination of potency. Dev Biol Stand 97: 61-71.
131. Toon S,. 1996. The relevance of pharmacokinetics in the development of biotechnology products. Eur J Drug Metab Pharmacokinet 21: 93-103. (Pubitemid 26246152)
132. van de Weert M, Hennink WE, Jiskoot W,. 2000. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res 17: 1159-1167.
133. van den Broek I, Sparidans RW, Huitema AD, Schellens JH, Beijnen JH,. 2006. Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 837 (1-2): 49-58. (Pubitemid 43796292)
134. van den Broek I, Sparidans RW, Schellens JHM, Beijnen JH,. 2007. Enzymatic digestion as a tool for the LC-MS/MS quantification of large peptides in biological matrices: Measurement of chymotryptic fragments from the HIV-1 fusion inhibitor enfuvirtide and its metabolite M-20 in human plasma. J Chromatogr B 854: 245-259. (Pubitemid 46970742)
135. van den Broek I, Sparidans RW, Schellens JH, Beijnen JH,. 2008. Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 872 (1-2): 1-22. Review.
136. Vergote V, Van Dorpe S, Peremans K, Burvenich C, De Spiegeleer B,. 2008. In vitro metabolic stability of obestatin: Kinetics and identification of cleavage products. Peptides 29 (10): 1740-1748.
137. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M,. 2010. Synthetic therapeutic peptides: Science and market. Drug Discov Today 15 (1-2): 40-56.
138. Voet D, Voet JG,. 1995. Biochemistry. New York: John Wiley & Sons. p. 71.
139. Wacher VJ, Silverman JA, Zhang Y, Benet LZ,. 1998. Role of p-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87: 1322-1330.
140. Walsh G,. 2003. Biopharmaceuticals-Biochemistry and biotechnology. New York: John Wiley & Sons. pp. 499-507.
141. Walsh G,. 2006. Biopharmaceutical benchmarks 2006. Nat Biotechnol 24 (7): 769-776. (Pubitemid 44086612)
142. Watson DG, Atsriku C, Oliveira EJ,. 2003. Review role of liquid chromatography-mass spectrometry in analysis of oxidation products and antioxidants in biological systems. Anal Chim Acta 492: 17-47. (Pubitemid 37101389)
143. Watt PM,. 2006. Screening for peptide drugs from the natural repertoire of biodiverse protein folds. Nat Biotechnol 24: 177-183. (Pubitemid 43221700)
144. Whitehouse CM, Dreyer RN, Yamashita M, Fenn JB,. 1985. Electrospray interface for liquid chromatographs and mass spectrometers. Anal Chem 57: 675-679. (Pubitemid 15479593)
145. Wild D,. 1994. The immunoassay book. New York: Stockton Press.
146. Worth GK, Vasikaran SD, Retallack RW, Musk AA, Gutteridge DH,. 2004. Major method-specific differences in the measurement of intact parathyroid hormone: Studies in patients with and without chronic renal failure. Ann Clin Biochem 41: 149-154. (Pubitemid 38523602)
147. Yang Z, Wang S,. 2008. Recent development in application of high performance liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressants. J Immunol Methods 336 (2): 98-103.
148. Yang JZ, Bastiab KC, Moore RD, Stobaugh JF, Borchardt RT,. 2002. Quantitative analysis of a model opioid peptide and its cyclic prodrugs in rat plasma using high-performance liquid chromatography with fluorescence and tandem mass spectrometric detection. J Chromatogr B 780: 269-281. (Pubitemid 35223562)
149. Youn YS, Jung JY, Oh SH, Yoo SD, Lee KC,. 2006. Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: Stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J Control Release 114: 334-342. (Pubitemid 44310815)
150. Youn YS, Chae SY, Lee S, Jeon JE, Shin HG, Lee KC,. 2007. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment, insulinotropic activity, glucose-stabilizing capability and proteolytic stability. Biochem Pharmacol 73: 84-93. (Pubitemid 44853930)
151. Yuan L, Wang J, Shen WC,. 2008. Lipidization of human interferon-alpha: A new approach toward improving delivery of protein drugs. J Control Release 129: 11-17.
152. Zasloff M,. 2002. Antimicrobial peptides of multicellular organisms. Nature 415: 389-395. (Pubitemid 34100944)
153. Zhang CX, Weber BV, Thammavong J, Grover TA, Wells DS,. 2006. Identification of carboxyl-terminal peptide fragments of parathyroid hormone in human plasma at low picomolar levels by mass spectrometry. Anal Chem 78: 1636-1643. (Pubitemid 43346303)
154. Zheng K, Lubman DM, Rossi DT, Nordblom GD, Barksdale CM,. 2000. Elucidation of peptide metabolism by on-line immunoaffinity liquid chromatography mass spectrometry. Rapid Commun Mass Spectrom 14 (4): 261-269. (Pubitemid 30100852)